The 3.2019 version of NCCN guidelines (National Comprehensive Cancer Network (NCCN), 2019) for pancreatic cancer recommends that all patients with pancreatic cancer should be sequenced to determine their BRCA1/2 mutation status. The gene discussed is BRCA1; the disease is pancreatic neoplasm.